Type 1 diabetes (T1D) is a selective autoimmune loss of insulin-secreting pancreatic β-cells and lifelong replacement with exogenous insulin. The disease remains incurable despite extensive research. New therapies, such as stem cell replacement, have been developed as the leading β-cell replacement modality. Pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have been established as insulin-secreting cells, a theoretically unlimited reservoir for transplantation. Defective β-cell function, immune rejection, and ethical issues still exist. New immunosuppressive measures such as costimulation blockade therapy or regulatory T cell (Treg)-based therapy have been proposed to optimize graft survival with fewer side effects. Bioengineered islet grafting, xenograft transplantations, and gene editing tools are also analyzed in order to improve the effectiveness of β-cell replacement. Therapeutic advances in target immunomodulation and islet encapsulation are also enhancing survival and functionality of transplanted cells. This article provides a pharmaceutical review of emerging β-cell replacement therapies including stem cell-derived therapy, immunotherapy, and innovative biotechnologybased solutions. Breaking through current limitations of these therapies is crucial to achieving long-term insulin independence for T1D patients. Refining differentiation protocols, improving immune evasion strategies, and merging paradigms of personalized medicine are essential to achieving maximal therapeutic benefit in future studies.
Dushyant, Smita Narwal, Gurvirender Singh et al.· Recent advances in inflammat...· 0 citations
Type 1 diabetes (T1D) continues to be a complex, multifactorial autoimmune condition
characterized by targeted destruction of pancreatic β-cells and permanent insulin dependence. How
tremendous the change has been since the advent of insulin therapy, yet T1D patients remain at
catastrophic risk from acute complications and chronic vascular injury, calling for more potent
disease-modifying therapies. Developments in immunology and genetics have unraveled the interaction
of environmental trigger events, including viral infection and gut microbiota, with genetic
susceptibility, i.e., HLA class II alleles, on the aberration of immune tolerance and induction of β-
cell autoimmunity. The last few decades have seen remarkable advances in the pathogenesis of
T1D, including the discovery of β-cell autoantibodies and the pivotal role of autoreactive T cells.
However, therapeutic trials in humans of immunomodulatory interventions, such as cyclosporine,
anti-CD3 antibodies, and tolerogenic dendritic cells, have, to date, shown only temporary preservation
of native insulin secretion, with safety limitations or failure to sustain efficacy being significant
limitation. In parallel, efforts at inducing antigen-specific tolerance and microbiota modification
have been promising in preclinical models but are still to be validated in humans. Technological
advances, including continuous glucose monitoring and artificial pancreas systems, have enhanced
glycemic management and quality of life without influencing causative autoimmunity.
New strategies, β-cell replacement by transplant or xenograft, genetic engineering to favor immune
evasion, and gene therapy for insulin production promise more definitive cures, but much remains
in the path of safety, immune rejection, and long-term efficacy. Finally, in the years to come, the
management of T1D will be a blend of early diagnosis, customized immunomodulation, improved
sensing of glucose, and regeneration. Research on the genetic, immunologic, and environmental
determinants for T1D and the creation of safer and more potent therapies will continue to be needed
to advance beyond disease symptomatology management to disease modification and prevention.
Jasvinder Saini, Dushyant, Jagdeep Singh et al.· Current Topics in Medicinal...· 0 citations